Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α
ASTRID M. PEDERSEN(Danish Cancer Society), Christina W. Yde(University of Southern Denmark)
Cited by 19
Related Papers
Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1
|International Journal of Oncology|2006|72
A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma
|Cancer Genetics|2016|38